Lenzilumab, Humanigen Inc.’s lead candidate, undershot statistical significance on the primary endpoint in the U.S. NIH-sponsored ACTIV-5/BET-B study of treating hospitalized COVID-19 patients. The Short Hills, N.J.-based company’s stock (NASDAQ:HGEN) crumpled in the wake of the results. Read More
Atara Biotherapeutics Inc.’s eagerly awaited update on the phase II Embold study testing ATA-188 in progressive multiple sclerosis (MS) left investors scratching their heads, and shares (NASDAQ:ATRA) closed at $3.89, down $4.77, or 55%. Read More
Merck & Co. Inc. has snagged a $290 million development and marketing deal for Orion Corp.’s potential oral prostate cancer drug, ODM-208, which aims to suppress production of hormones that drive this form of cancer. Read More
Agomab Therapeutics NV raised $40.5 million in a series B extension led by Pfizer Inc., which has also come on board as an adviser on the development of AGMB-129, Agomab’s candidate therapy for fibrostenotic Crohn’s disease. The new cash raises the series B total to $114 million. Read More
COVID-19 is the unwanted gift that keeps on giving. The U.S. CDC unwrapped one of those “presents” in a July 12 report that showed the threat of antimicrobial-resistant (AMR) infections has worsened — with resistant hospital-onset infections and deaths in the U.S. each increasing at least 15% during the first year of the pandemic. Read More
Biopharmas raising money in public or private financings, including: Applied, Gossamer, Histogen, Mosanna, Pliant, Shuttle, Theratechnologies. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Clinilabs, Connect, Endogena, Leap, Moderna, Oncotelic, Propanc, Pulmatrix, Scpharmaceuticals, Tetra, Vasopharm, Verve. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Glycotope, Legochem, Lqt, Neuraxpharm, Nurexone, Orion, Peptilogics, Polyrizon, Prokidney, RS, Sanofi, Thryv. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Basilea, Bellus, Byondis, Citius, Cyxone, Dyne, Fresenius, Greenwich, Novartis, Y-mabs. Read More
